Pfizer Inc. (PFE) said the company's investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy (DMD) received Fast Track designation from the FDA. The designation was granted based on data from the phase 1b study that indicated that the intravenous administration of PF-06939926 was well-tolerated during the infusion period and dystrophin expression levels were sustained over a 12-month period.
from RTT - Biotech https://ift.tt/3cMGP7L
via IFTTT
No comments:
Post a Comment